leisure time -WSS

leisure time

author：explore 2025-09-29 01:45:52 - browse：19

At some point this summer, the drugmaker Novo Nordisk will release results from a closely watched study that, if successful, could further uncork demand for new obesity medications, streamline insurance coverage for the therapies, and demonstrate long-lasting health benefits.

The Select trial, as the study is called, is the first large, randomized trial to test whether long-term treatment with a weight loss drug can meaningfully improve patients’ cardiovascular health. Novo is testing Wegovy, a weekly injection also sold under the brand name Ozempic for type 2 diabetes, against placebo in the five-year study.

The implications are massive, and not just for Novo. Wegovy is part of a class of medicines that target a hormone called GLP-1, which curbs patients’ appetites. Those drugs have demonstrated an ability to help people lose dramatic amounts of weight in clinical trials, but payers, including Medicare, have been slow to reimburse for them without definitive data on their long-term health benefits.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

WSS

Steward Health Care Massachusetts hospitals face fiscal disaster

John Green on his newest strategy for fighting tuberculosis

Boston's new lab space is opening empty

First U.S. drug developed to treat liver disease MASH is approved

First U.S. drug developed to treat liver disease MASH is approved

Amid AI frenzy, a top HHS official's quest to create safeguards

entertainment

leisure time

leisure time

Bright Health sells Medicare Advantage business to Molina

A solution to the after

Wildfire smoke exposes gaps in outdoor worker protections

Amid AI frenzy, a top HHS official's quest to create safeguards

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

HHS secretary Becerra pressed on Change HealthCare cyberattack

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Why palliative psychiatry is worth discussing

Dobbs anniversary: the lost opportunity of abortion as health care

6 phony surgeries that take placebo to the extreme

hotspot

Why palliative psychiatry is worth discussing

NIH study of ME/CFS points to clear biological hallmarks

He's a Nobel laureate. Critics say he was misleading on Covid

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

Male and female sex labels in research insufficient, scientists say

As AI in medicine takes off, can 'human in the loop' prevent harm?

focus

focus

knowledge

explore